By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Arbutus Biopharma (Formerly Known As Tekmira Pharmaceuticals Corporation) 

US LOCATION:
3805 Old Easton Road
Doylestown, PA 18902

CAN LOCATION:
8900 Glenlyon Parkway

Burnaby,  British Columbia,  V5J 5J8  Canada
Phone: 604-419-3200 Fax: 604-419-3201


SEARCH JOBS

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

In addition to our HBV Assets, we are developing a pipeline of oncology, anti-viral and metabolic programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.


Key Statistics


Email: careers@arbutusbio.com
Ownership: Subsidiary

Web Site: Arbutus Biopharma
Employees: <500 Employees
Symbol: TKMR
 









Company News
Tekmira (TKMR) Changes Name to Arbutus Biopharma, Kills Ebola Program and Focuses on Hepatitis B 7/20/2015 7:19:05 AM
Tekmira (TKMR) Provides Update On TKM-Ebola-Guinea 6/19/2015 7:11:53 AM
Tekmira (TKMR) To Present At JMP Securities Life Sciences Conference 6/18/2015 7:51:26 AM
Tekmira (TKMR) To Present at Jefferies and Co. 2015 Healthcare Conference 5/21/2015 4:24:44 PM
Tekmira (TKMR) Provides Corporate Update And Announces First Quarter 2015 Results 5/7/2015 8:01:57 AM
Tekmira (TKMR) To Present At Deutsche Bank (DB) Health Care Conference 5/4/2015 10:42:12 AM
Tekmira (TKMR) Conference Call And Webcast Advisory Corporate Update And First Quarter Financial Results 4/23/2015 10:40:05 AM
Tekmira (TKMR) And Collaborators Publish Positive Preclinical Ebola Survival Data In Nature Journal 4/22/2015 1:22:57 PM
FDA Modifies Partial Clinical Hold On Tekmira (TKMR)'s TKM-Ebola IND To Allow Multiple Dosing Of Healthy Volunteers 4/10/2015 8:32:08 AM
Tekmira (TKMR) Presents Preclinical Results Demonstrating Super-Additive Effects On Plasma Triglyceride Lowering By Silencing Of Apoc3 And ANGPTL3 Genes 3/26/2015 6:54:31 AM
12345678910...
//-->